High-dose infliximab for treatment of pediatric ulcerative colitis: A survey of clinical practice

World Journal of Gastroenterology

Volumn 18, Issue 11, 2012, Pages 1229-1234

  Nattiv, Roy ^a   Wojcicki, Janet M ^a   Garnett, Elizabeth A ^a   Gupta, Neera ^a   Heyman, Melvin B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Children; Immunosuppression; Inflammatory bowel disease; Pharmacology; Ulcerative colitis

Indexed keywords

INFLIXIMAB;

ARTICLE; CLINICAL PRACTICE; COLON RESECTION; DRUG MEGADOSE; HUMAN; PEDIATRICS; ULCERATIVE COLITIS;

EID: 84858788634     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v18.i11.1229     Document Type: Article

References (12)

1. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476
2. Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Stephens M, Evans J, Otley A, Carvalho R, Mack D, Bousvaros A, Rosh J, Grossman A, Tomer G, Kay M, Crandall W, Oliva-Hemker M, Keljo D, LeLeiko N, Markowitz J. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol 2010; 105: 1430-1436
3. US Food and Drug Administration. Medication Guide for Remicade (Rem-eh-kaid) (Infliximab). Centocor Ortho Biotech Inc. February 2011. Available from: URL: http: //www. accessdata.fda.gov. Accessed June 22, 2011
4. American Board of Pediatrics. The American Board of Pediatrics 2009-2010 Workforce Data. Available from: URL:https://www.abp.org. Accessed December 31, 2010
5. Mamula P, Markowitz JE, Cohen LJ, von Allmen D, Baldassano RN. Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr 2004; 38: 298-301
6. Mackey AC, Green L, Leptak C, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr 2009; 48: 386-388
7. Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-608
8. Sokol H, Seksik P, Carrat F, Nion-Larmurier I, Vienne A, Beaugerie L, Cosnes J. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010; 59: 1363-1368
9. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-1395
10. Lichtenstein GR, Diamond RH, Wagner CL, Fasanmade AA, Olson AD, Marano CW, Johanns J, Lang Y, Sandborn WJ. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009; 30: 210-226
11. Overview of the Exception and Appeals Process. Centocor Ortho Biotech Inc. April 2009. Available from: URL: http://www.centocoraccessone.com. Accessed September 12, 2010.
12. Rutgeerts P, Vermeire S, Van Assche G. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009; 136: 1182-1197